Applications Invited for THE HORIZON PRIZE 2022: MIT Solve


Challenge Overview

For the more than 400 million people living with rare diseases, the journey towards diagnosis is often long and complex. Even when a rare disease has been identified, treatment options are scarce—over 95% of rare diseases have no approved treatments. Meanwhile, people also need support while living with the symptoms of rare diseases and the possibility of disease progression.

Thank you for reading this post, don't forget to subscribe!

Technology can be a powerful tool for optimizing the well-being of people living with rare diseases. Educational tools can help patients better understand their diagnosis, and peer support networks can address the isolation that can accompany such knowledge. For health care providers, using technology can support clinical decision making to serve their patients more effectively.

The Horizon Prize, powered by MIT Solve, seeks technology-based solutions that improve the quality of life of people who have been diagnosed with a rare disease. To that end, the Prize seeks solutions that:

  • Optimize holistic care for people with rare diseases—including physical, mental, social, and legal support;
  • Support daily care management for patients and/or their caregivers;
  • Mitigate barriers to accessing medical care after diagnosis which disproportionately affect disinvested communities and historically underrepresented identity groups;
  • Enhance coordination of care and strengthen data sharing between health care professionals, specialty services, and patients;
  • Empower patients with quality information about their conditions to fight stigma associated with rare diseases; and
  • Promote community and connection among rare disease patients and their advocates.

Want to learn more about this Challenge? Sign up to receive email updates here


Disclaimer : We try to ensure that the information we post on is accurate. However, despite our best efforts, some of the content may contain errors. You can trust us, but please conduct your own checks too.